News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
ArriVent BioPharma (NASDAQ:AVBP) experienced a 4.7% drop in share price after reporting weaker-than-expected quarterly earnings, missing analyst estimates by $0.06 with a $1.05-per-share loss. Despite the share price decline and significantly lower trading volume, analyst sentiment remains largely positive, holding a "Moderate Buy" consensus …
Tema ETFs LLC has acquired a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP), purchasing 57,034 shares valued at approximately $1.98 million, representing a 0.12% stake. This investment is part of broader institutional interest, with other major firms also adjusting their holdings in the company. …
ArriVent BioPharma (AVBP) is making strong clinical progress with its late-stage oncology pipeline, particularly with firmonertinib for EGFR-mutant NSCLC. The company also has next-generation ADCs targeting GI and solid tumors advancing. Significant clinical and financial milestones are anticipated in the second half of 2026.
ArriVent BioPharma (NASDAQ:AVBP) reported a quarterly loss of $1.05 per share, missing analysts' consensus estimates by $0.07. Despite the earnings miss, the company's shares rose by 0.2% to $31.46, and institutional investors own 9.48% of the stock. Analyst sentiment remains "Moderate Buy" with an …
ArriVent BioPharma (AVBP) reported its Q2 2026 financial results, including $373.1 million in cash and investments, projected to fund operations into 2028. The company anticipates topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC in the second …
ArriVent BioPharma (AVBP) is anticipated to release its Q2 2026 earnings before market open on Friday, August 14th. Analysts project a loss of $0.98 per share, following a $0.96 loss in the previous quarter which missed estimates. The stock currently holds a "Moderate Buy" …
This article provides an AI-generated analysis for Arrivent Biopharma Inc. (AVBP), highlighting a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It details specific institutional trading strategies (Long, Momentum Breakout, Short) with entry, target, and stop-loss levels, and offers …
ArriVent BioPharma (NASDAQ:AVBP) has received a "Moderate Buy" consensus from analysts, with an average 12-month price target of $44.83. The company, a clinical-stage biopharmaceutical firm, opened at $29.82 with a market capitalization of approximately $1.39 billion. Despite missing quarterly earnings estimates with a loss …
This article provides a detailed overview of Arrivent Biopharma Inc (AVBP) stock, highlighting its current trading price, market capitalization, and a general lack of a comprehensive stock score due to insufficient data. It further explains TradingKey's methodology for generating various stock scores, such as …
This article presents the quarterly and annual balance sheets for Arrivent Biopharma Inc (AVBP), detailing its financial health through assets, liabilities, and shareholders' equity. It includes key financial metrics like cash and short-term investments, total assets, current assets, and liabilities, alongside FAQs explaining the …
This article provides an overview of Arrivent Biopharma Inc's (AVBP) dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock …
This article provides a brief overview of institutional shareholding in Arrivent Biopharma Inc (AVBP). It lists the top institutional shareholders, their shareholdings, and the percentage change in their positions. The company's current stock price, market cap, and links to other financial analysis tools are …
This article provides an in-depth analysis of Arrivent Biopharma Inc's (AVBP) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial data spanning several years, highlighting trends and specific figures for various cash flow components. The document also includes …
This article provides valuation details for Arrivent Biopharma Inc (AVBP), highlighting its current stock price, market capitalization, and a negative P/E TTM. It indicates key financial metrics and navigation points for further analysis of the company on the TradingKey platform.
This article provides a technical analysis of Arrivent Biopharma Inc (AVBP) stock, detailing various indicators and moving averages. It offers insights into the stock's current technical ratings, which show a neutral signal based on moving averages and other technical indicators. The analysis includes values …
This article provides a basic overview of ArriVent BioPharma, Inc. (NASDAQ: AVBP) on TradingView. It indicates that the primary content would typically include financial data, statements, statistics, dividends, earnings, and segment analysis, but these sections are not populated in the provided text. The article …
Arrivent Biopharma Inc (AVBP) closed at $31.750, up 0.67%, with a market capitalization of $1.44 billion. Analysts have a "Buy" rating for AVBP with a target price of $43.917, indicating over 55% upside potential. The company is a clinical-stage biopharmaceutical firm focused on developing …
This article provides the quarterly and annual income statements for Arrivent Biopharma Inc (AVBP), detailing its financial performance including operating expenses, R&D expenses, operating profit, net non-operating interest income, and net income. It also includes frequently asked questions about interpreting income statements and key …
This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also provides multi-timeframe signal analysis, …
BTIG has reiterated its Buy rating for ArriVent BioPharma (AVBP.US) and maintained its price target of $42. This sustained positive outlook suggests continued confidence in the company's prospects by the investment firm.
Search by ticker symbol or company name and select a result to open its chart.